Cross-tissue comparisons of leptin and adiponectin

Abstract

DNA methylation has been mostly studied in circulating blood cells. Although being readily accessible, metabolically active tissues such as adipose tissue would be more informative for the study of metabolic disorders. However, whether or not the blood DNA methylation profile correlates with that of adipose tissue remains unknown. In this study, DNA methylation patterns of variation at LEP and ADIPOQ gene loci were similar between individual CpGs across the different tissues. We also report that DNA methylation levels at biologically relevant CpGs are correlated between blood, subcutaneous, and visceral adipose tissue, and that these nearby CpGs are associated with LEP and ADIPOQ gene expression in adipose tissues. These results will be highly relevant for future epigenetic studies in metabolic disorders.

Keywords: :

• epigenetics
• blood
• subcutaneous adipose tissue
• visceral adipose tissue

Introduction

The LEP and ADIPOQ genes, encoding for leptin and adiponectin respectively, have drawn much attention in candidate gene studies on obesity and its related metabolic disorders. These adipokines are mainly produced and secreted by adipocytes and are important regulators of energy metabolism and insulin sensitivity.^1,2 Recent studies suggested that these two adipokines are involved in the fetal metabolic health programing of the newborn through epigenetic adaptations in response to a changing in utero environment. Indeed, we have recently reported correlations between placental DNA methylation levels at the LEP and ADIPOQ gene loci and maternal blood glucose concentrations (2 h post oral glucose tolerance test) at second trimester of pregnancy.^3-5 A high maternal glucose concentration has been previously associated with a long-term susceptibility to obesity and related metabolic disorders in the newborn.^6-8 Moreover, Tobi et al.⁹ have observed higher LEP DNA methylation levels in leukocytes of men exposed prenatally to the ending World War 2 Dutch famine in comparison with unexposed siblings, suggesting that epigenetic marks imprinted during fetal life at the LEP locus could last over 60 y after birth.

DNA methylation marks consist in the addition of a methyl group at position 5′ of the pyrimidine ring of the cytosines upstream of a guanine (dinucleotide CpG) catalyzed by DNA methyltransferases.^10,11 The establishment of DNA methylation marks during fetal life is crucial for cellular differentiation, X chromosome inactivation, genomic imprinting, and normal embryonic development.^12,13 Embryonic DNA methylation marks are mitotically stable thus they can have a long-term functional impact and can be partially transmitted to the next generation.^14-18 Although transcriptional regulation through DNA methylation is tissue-specific,^19-21 it has been suggested that embryonic epigenetic marks set early during cellular differentiation and division are similar in various tissues.^22-24 These similarities could be of importance when access to metabolically active tissues (e.g., adipose tissue) is limited, and especially when studying epigenetically affected genes in the context of in utero or fetal metabolic programming.

The objective of the current study was to compare LEP and ADIPOQ epigenetic profiles in blood, subcutaneous (SAT), and visceral (VAT) adipose tissue samples from the same obese class III²² subjects in order to characterize tissue-specific DNA methylation at these two adipokine gene loci. The comparison of adipokine DNA methylation levels in blood and adipose tissues will tell us whether or not readily accessible blood cells can reflect the DNA methylation profile of metabolically active tissues and can eventually be used to predict a lifelong susceptibility to obesity and associated metabolic disorders.

Results and Discussion

DNA methylation and mRNA level analyses at the LEP gene locus

Blood, SAT, and VAT were obtained from 73 obese class III²² subjects with body mass index (BMI) ranging from 40.0 to 60.0 kg/m² (mean: 49.6 ± 6.0 kg/m²) (sample characteristics in Table S1). DNA methylation levels were assessed in blood, SAT, and VAT at 21 CpGs out of the 31 that we³ and Melzner et al.²⁵ have previously epigenotyped in the proximal promoter CpG island of the LEP gene (Fig. S1).

DNA methylation levels at these 21 CpG sites analyzed within the LEP gene promoter were found to be highly variable within the region and across the three tissues analyzed. On average, the correlation coefficients between DNA methylation levels at these 21 CpG sites were found to be modest to very high in blood (r = 0.12 to 0.92), SAT (r = 0.01 to 0.82), and VAT (r = 0.01 to 0.86) (Fig. S3). For most of the CpG sites analyzed, methylation values were 1.5 to 2.0 times higher in blood than in SAT and VAT (Fig. 1A). These results confirm previous findings from Marchi et al.²⁶ and Stoger et al.²⁷ showing that LEP DNA methylation is higher in tissues known to express lower LEP mRNA levels. The highest DNA methylation differences (>10.0%) between blood and adipose tissues at the LEP gene promoter locus were observed at CpG4, CpG11, CpG24, CpG29, CpG30, and CpG31 with CpG11 being the most significant (Fig. S1). Interestingly, CpG4 is found on the macrophage migration inhibitory factor (MIF-1) transcription factor binding site (TFBS) and CpG11 on or nearby the CCAAT/enhancer binding protein (C/EBP), hepatic leukemia factor (HLF), and c-MYB TFBS suggesting that these CpG sites may be important for tissue-specific LEP expression regulation (Fig. S2). The functional significance of CpG11 is also supported by its location within a highly conserved region across all placental mammals (Fig. S2). This CpG site was previously shown to be strongly differentially methylated between tissues with low (liver) and high (visceral adipocyte) mRNA levels of LEP.²⁶ Moreover, the regulation of LEP gene promoter activity by DNA methylation at C/EBP TFBS has previously been reported.²⁵ No transcriptional regulatory element was identified at CpG24, CpG29, CpG30, and CpG31 of the LEP gene promoter.

Figure 1. DNA methylation levels at LEP gene promoter (A) and ADIPOQ CpG island E (B). CpG sites in blood (white), subcutaneous (black), and visceral (gray) adipose tissues (n = 73). Error bars represent the standard deviation (SD). Mean DNA methylation levels were compared with the paired sample Student t test. Bars with different letters indicate means that are significantly different from each other (P ≤ 0.05) after adjustment for multiple testing.

Next, we report that the correlation between DNA methylation levels at each individual CpG site was tissue- and site-specific. After multiple testing corrections, LEP DNA methylation levels at 14 individual CpG sites were found to be significantly correlated between SAT and VAT, whereas 6 and 2 CpGs were significantly correlated between blood and SAT and blood and VAT, respectively (Table 1). Interestingly, DNA methylation at CpG11, localized at C/EBP TFBS, was found to be among the most highly correlated between SAT and VAT and between SAT and blood (Table 1). For this site, a trend for association was also observed between VAT and blood after multiple testing correction (r = 0.327; P = 0.10). CpG16 was also found to be highly correlated between the three tissues and CpG17 was correlated between SAT and blood (Table 1). These two CpG sites are localized within SP1 TFBS and a highly conserved region of the LEP gene promoter locus (Fig. S2). SP1 TFBS was shown to be involved in the regulation of LEP gene expression.^25,28,29 High correlation coefficients were observed between DNA methylation levels at LEP CpG28 in the three tissues (Table 1). Nevertheless, the cytosine at this CpG site was found to be polymorphic (single nucleotide polymorphism [SNP]; rs791620; C > A), and the genotype is likely driving the correlations observed. Among all the CpG sites analyzed in the current study, CpG11, CpG16, and CpG17 are the most promising as they are located in potentially functional regions and correlated between blood and adipose tissues. Nevertheless, further studies are needed to determine whether these CpGs are associated with the development of obesity in normal weight and obese populations. If such associations are observed, it could eventually raise the possibility of using blood LEP DNA methylation levels at these CpG sites as a surrogate for LEP DNA methylation levels in adipose tissues and as a marker of obesity susceptibility.

Table 1. Pearson correlation coefficients between DNA methylation levels at LEP gene promoter CpG sites in blood, subcutaneous (SAT), and visceral adipose (VAT) tissues

CpG sites	Chromosomal location^a	SAT vs. VAT	SAT vs. blood	VAT vs. blood
LEP-CpG3	chr7:127 881 368	0.295	-0.102	0.226
LEP-CpG4	chr7:127 881 349	0.589**	0.116	0.287
LEP-CpG5	chr7:127 881 343	0.414**	0.073	0.195
LEP-CpG6	chr7:127 881 338	0.435**	0.049	0.220
LEP-CpG7	chr7:127 881 329	0.367*	-0.049	0.189
LEP-CpG11	chr7:127 881 279	0.575**	0.433**	0.327
LEP-CpG12	chr7:127 881 268	0.142	0.160	0.156
LEP-CpG13	chr7:127 881 259	0.087	0.166	0.132
LEP-CpG14	chr7:127 881 256	0.134	0.447**	0.334
LEP-CpG15	chr7:127 881 245	0.079	0.213	0.232
LEP-CpG16	chr7:127 881 235	0.352*	0.488**	0.358*
LEP-CpG17	chr7:127 881 230	0.284	0.578**	0.268
LEP-CpG23	chr7:127 881 170	0.500**	0.339	0.203
LEP-CpG24	chr7:127 881 168	0.484**	0.408**	0.217
LEP-CpG25	chr7:127 881 160	0.202	0.186	0.315
LEP-CpG26	chr7:127 881 147	0.484**	0.311	0.289
LEP-CpG27	chr7:127 881 144	0.497**	0.240	0.232
LEP-CpG28	chr7:127 881 142	0.773**	0.611**	0.573**
LEP-CpG29	chr7:127 881 130	0.451**	0.212	0.205
LEP-CpG30	chr7:127 881 128	0.490**	0.277	0.310
LEP-CpG31	chr7:127 881 126	0.508**	0.200	0.204
LEP-MEAN	-	0.571**	0.321	0.354*

Statistically significant after corrections for multiple testing: **P ≤ 0.01 and *P ≤ 0.05. ^aUCSC Genome Browser on Human Feb. 2009 (Feb. 2014).

LEP gene expression analysis in SAT and VAT confirmed the functional importance of specific CpG sites in both adipose tissues. Considering that LEP expression is influenced by sex^30,31 and that associations between LEP DNA methylation and phenotypic variables have been previously reported to be sex-specific,^9,32,33 the relationships between LEP DNA methylation and mRNA levels were adjusted for sex. In addition, we observed significant interactions between sex and DNA methylation levels (CpG12 and CpG14) on VAT LEP mRNA levels. In VAT, DNA methylation levels at LEP CpG7, CpG11, and CpG27 to CpG30 were found to be positively associated with LEP mRNA levels (Table 2). These results are not supported by previous studies reporting negative associations between mean LEP promoter DNA methylation and expression in the visceral adipocyte fraction,²⁶ placenta,³ and adipocyte cell cultures.²⁵ These contrasting results might be explained by the fact that LEP genetic variations were not taken into account in these studies. Indeed, an exploratory analysis revealed that LEP rs2167270, a variant previously associated with LEP expression,³⁴ tended to be associated with LEP gene expression in VAT (P = 0.06) and was significantly associated with DNA methylation levels at CpG4 in SAT and at CpG3, CpG4, CpG6, and CpG7 in VAT (Table S2). In addition, rs2167270 was found to influence the relationship between LEP DNA methylation and mRNA levels in adipose tissues (Table 2). In VAT, positive significant correlation coefficients were found in GG genotypes for CpG11 and nearby CpG sites, while no correlation was observed in GA/AA genotypes (Table 2). Interestingly, in SAT a statistical interaction effect was observed between the rs2167270 genotype and LEP DNA methylation levels (CpG5 [p_i = 0.03], CpG14 [p_i = 0.01], CpG15 [p_i = 0.012], and CpG25 [p_i = 0.009]) on LEP mRNA levels. We observed that LEP DNA methylation levels (CpG14, CpG17, CpG23, CpG24, and CpG25) were negatively correlated with LEP mRNA levels in carriers of the A allele, and they tended to be positively correlated in the GG genotype at CpG14 and CpG25. These exploratory analysis results highlight, for the first time, the importance of both genetic and epigenetic variations in the regulation of LEP gene expression. Furthermore, they suggest that LEP gene expression regulation in SAT and VAT is independent and restricted to specific CpG sites. In VAT, CpG sites located close to CpG11; nearby the TATA box element and the C/EBP TFBS appear to be the most important regulator of LEP expression whereas in SAT, CpG sites near SP1 TFBS (CpG16 and CpG17) may be central (Fig. S2). Further studies are needed to determine the contribution of the other SNPs (rs791620 and rs34104384) in the regulation of LEP gene expression in both types of adipose tissue. In addition, these preliminary genetic results will need to be confirmed in samples of larger size.

Table 2. Pearson correlation coefficients between DNA methylation and mRNA levels at LEP gene promoter CpG sites in subcutaneous (SAT) and visceral adipose (VAT) tissues according to rs2167270 genotype and adjusted for sex

	SAT			VAT
	ALL^a	GG^a	GA/AA^a	ALL^a	GG^a	GA/AA^a
n	73	30	43	73	30	43
LEP-CpG3	−0.079	0.145	−0.215	0.070	0.286	−0.068
LEP-CpG4	−0.093	0.243	−0.294^†	0.201	0.266	0.194
LEP-CpG5	−0.060	0.318^†	−0.300^†	0.173	0.294	0.061
LEP-CpG6	−0.051	0.267	−0.239	0.211^†	0.350^†	0.093
LEP-CpG7	−0.076	0.228	−0.249	0.320*	0.575**	0.139
LEP-CpG11	−0.056	0.018	−0.070	0.290*	0.390*	0.238
LEP-CpG12	−0.124	0.004	−0.239	0.086	0.281	−0.039
LEP-CpG13	−0.057	0.192	−0.206	0.308*	0.627**	0.125
LEP-CpG14	−0.126	0.324^†	−0.497**	0.222^†	0.322^†	0.147
LEP-CpG15	−0.065	0.328^†	−0.285^†	0.180	0.281	0.097
LEP-CpG16	−0.093	0.031	−0.173	0.125	0.371*	0.003
LEP-CpG17	−0.172	0.078	−0.367*	0.103	0.212	0.014
LEP-CpG23	−0.168	0.083	−0.340*	0.225^†	0.200	0.256
LEP-CpG24	−0.134	0.202	−0.333*	0.114	0.117	0.116
LEP-CpG25	−0.093	0.329^†	−0.345*	0.193	0.152	0.207
LEP-CpG26	0.048	0.395*	−0.194	0.268*	0.282	0.264
LEP-CpG27	0.006	0.315	−0.238	0.301*	0.250	0.352
LEP-CpG28	−0.012	0.069	−0.090	0.265*	0.351^†	0.180
LEP-CpG29	−0.036	0.203	−0.217	0.252*	0.175	0.322
LEP-CpG30	−0.094	0.117	−0.233	0.215*	0.239	0.212
LEP-CpG31	−0.068	0.079	−0.188	0.172	0.317^†	0.102
LEP-MEAN	−0.060	0.268	−0.265^†	0.297*	0.372*	0.241

^a Adjusted for sex. Statistically significant: **P ≤ 0.05 after corrections for multiple testing; *P ≤ 0.05 and ^†P ≤ 0.10 without correction for multiple testing.

DNA methylation and mRNA level analyses at the ADIPOQ gene locus

At the ADIPOQ gene locus, DNA methylation levels were assessed in the 73 patients at three polymorphic CpG islands (A, C, and E) as previously described (Fig. S3).⁴ DNA methylation levels at ADIPOQ CpG islands A and C were found to be hypomethylated (<10.0%) and hypermethylated (>90.0%), respectively in blood and both SAT and VAT (Fig. S3). The CpG sites localized in these CpG islands were considered unmethylated and fully methylated and were thus not further analyzed.

As observed for the LEP gene locus, mean DNA methylation levels at ADIPOQ-CpGE1, CpGE2, and CpGE3 were also found to be higher in blood (91.2 ± 2.4%) in comparison to SAT (81.2 ± 2.7%) and VAT (82.8 ± 3.3%) (Fig. 1B). At the ADIPOQ intron 1 locus, DNA methylation levels at CpGE1 and CpGE3 were highly correlated in SAT (r > 0.73; P < 0.001) and VAT (r > 0.73; P < 0.001), whereas in blood, the correlation was modest (r > 0.31; P < 0.01) (Fig. S5). DNA methylation levels at CpGE2 were the only ones significantly correlated between SAT and VAT after corrections for multiple testing (Table 3). CpGE2 DNA methylation was found to be negatively correlated with ADIPOQ mRNA levels in VAT, whereas in SAT, DNA methylation at CpGE3 was associated with ADIPOQ mRNA levels (Table 4). No transcriptional regulatory elements were identified at or near ADIPOQ CpG island E.

Table 3. Spearman rank correlation coefficients between DNA methylation levels at ADIPOQ CpG island E loci in blood, subcutaneous (SAT), and visceral adipose (VAT) tissues

CpG sites	Chromosomal location^a	SAT vs. VAT	SAT vs. blood	VAT vs. blood
ADIPOQ-CpGE1	chr3:186 562 911	0.241	−0.252	−0.207
ADIPOQ-CpGE2	chr3:186 562 915	0.411**	−0.038	0.145
ADIPOQ-CpGE3	chr3:186 562 950	0.283	−0.019	0.043
ADIPOQ-MEAN	-	0.324	−0.174	−0.024

Statistically significant after corrections for multiple testing: **P ≤ 0.01 and *P ≤ 0.05. ^aUCSC Genome Browser on Human Feb. 2009 (Feb. 2014).

Table 4. Pearson correlation coefficients between DNA methylation and mRNA levels at ADIPOQ CpG island E in subcutaneous (SAT) and visceral adipose (VAT) tissues

CpG sites	SAT^a	VAT^a
ADIPOQ-CpGE1	−0.164	−0.223^†
ADIPOQ-CpGE2	−0.078	−0.256*
ADIPOQ-CpGE3	−0.257*	−0.152

^a Adjusted for sex. Statistically significant: **P ≤ 0.05 after corrections for multiple testing; *P ≤ 0.05 and ^†P ≤ 0.10 without correction for multiple testing.

DNA methylation variations between CpG sites at the LEP and ADIPOQ gene loci

We also report that DNA methylation patterns of variation from one CpG site to the following were highly similar between the three tissues at both the LEP and ADIPOQ gene loci (Fig. 2). These similarities were previously observed by our group in cord blood and placenta samples⁵ and by Marchi et al.²⁶ in the liver, visceral adipocyte, and stromal vascular fraction of white adipose tissue at the LEP gene locus. Similarities between inter-individual CpG site variations at specific gene loci have also been reported in several other tissues.^24,35 Following these observations, we previously suggested that DNA methylation levels vary concurrently between tissues around predefined (heritable) values, which seem independent from one CpG site to another.¹⁵ Recently, Brons et al.³⁶ suggested that a detrimental fetal environment might decrease the acute regulation of the epigenome, which in turn might increase the risk to develop obesity and type 2 diabetes. This likely “predefined” pattern of DNA methylation that we and others have observed might be established early during embryonic development according to the maternal in utero environment and may determine the set point from which stochastic and environmental factors will induce a more or less acute regulation of the epigenome. Since this study was conducted with tissue samples from obese adults, longitudinal and dietary intervention studies will be needed to investigate whether LEP and ADIPOQ tissue-specific epipolymorphisms and associations are present in the newborn and normal weight populations, whether they predict the development of obesity or other metabolic disorders, and whether they respond to dietary and exercise interventions.

Figure 2. Average DNA methylation profile by CpG site for LEP gene promoter locus (A) and ADIPOQ CpG island E gene locus (B) in blood (white circles), subcutaneous (black circles), and visceral (gray circles) adipose tissues (n = 73).

In summary, the current study compared, for the first time, LEP and ADIPOQ DNA methylation levels in blood and adipose tissues. We report that DNA methylation patterns of variation between one CpG to the next at the LEP and ADIPOQ gene loci is highly similar between blood, SAT, and VAT, suggesting that a setting point for DNA methylation at each CpG site may exist. In addition, we showed that DNA methylation levels at potentially functional CpG sites are correlated between blood and adipose tissues. DNA methylation levels at or near these CpG sites were also found to be associated with adipokine gene expression levels. Hence, these specific CpGs might prove useful surrogates for DNA methylation measures, especially with SAT biopsies that require a much less invasive procedure than VAT sampling.

Materials and Methods

Patients

Blood, SAT, and VAT samples were obtained from 33 men and 40 pre-menopausal women (obese class III²²: BMI ≥ 40 kg/m²) undergoing biliopancreatic derivation to treat obesity. The 73 patients were free of treatment for dyslipidemia, diabetes, and hypertension. The surgical procedures have been previously described.^37,38 Briefly, fasting blood samples were taken on the morning or the day before the surgery. SAT and VAT samples were obtained at the beginning of the intervention. All samples were stored at −80 °C until nucleic acid extraction. Anthropometric parameters (body weight, height, waist, and hip circumferences), resting blood pressure, and fasting plasma insulin, glucose and lipid levels were also measured before surgery according to standardized procedures.³⁹ All participants provided a written informed consent before their inclusion in the study, and all clinical data were denominalized. This project was performed in collaboration with the Tissue bank for the study of obesity and its complications at the Institut Universitaire de Cardiologie et de Pneumologie de Québec. The project was approved by this institution’s and the Université Laval’s ethics committees and was conducted in accordance with the Declaration of Helsinki.

Nucleic acid extraction

DNA was purified from whole blood samples with the Gentra Puregene Blood Kit (Qiagen). DNA and RNA from SAT and VAT were extracted as previously described.⁴⁰ RNA quality was assessed with Agilent 2100 Bioanalyzer RNA Nano Chips (Agilent Technologies). Three RNA samples from SAT and VAT had low RNA integrity numbers (RIN < 6.0) and were excluded from the analysis. The other RNA samples in SAT and VAT showed a high quality with mean RIN values of 8.0 ± 0.8 and 8.3 ± 0.6 respectively.

DNA methylation analyses and genotyping

DNA methylation levels at CpG sites were assessed using pyrosequencing (Pyromark Q24, QIAGEN-Biotage). Combined with the NaBis DNA treatment, pyrosequencing is a quantitative real-time sequencing technology that allows to measure DNA methylation levels (%) at a single cytosine (CpG) of a given genomic region. NaBis treatment of DNA (EpiTect Bisulfite Kit, Qiagen) specifically converts unmethylated cytosines into uracil, while the methylated cytosines are protected from this transition creating a cytosine/thymine polymorphism. Once treated, NaBis-DNA is amplified (Pyromark PCR kit, Qiagen), and the cytosine and thymine alleles are quantified by pyrosequencing.⁴¹ DNA methylation levels at the LEP gene CpG island proximal promoter region were assessed using the PCR and pyrosequencing primers described in Table S3. Specific PCR and pyrosequencing conditions and primer pairs for ADIPOQ DNA methylation analyses were the same as previously described.⁴

Pyrosequencing technology was also used for genotyping a single nucleotide polymorphism (SNP; rs2167270; G > A) within the LEP proximal promoter region (Fig. S1). The genotype of the 73 patients was determined with the same PCR and sequencing primers as for the methylation analysis of CpG3 to CpG7 (Table S3). The pyrogram signals obtained, representing the amount of G and A nucleotides added to the sequence, allowed the quantification of the two alleles and determination of the genotype.⁴² The rs2167270 genotype was identical in all three tissues analyzed for the 73 patients. The genotype frequencies (GG: 30 [41.1%]; GA: 35 [47.9%] and AA: 8 [11.0%]) were found to be under Hardy–Weinberg equilibrium (P > 0.05). Carriers of the minor A allele (GA/AA) were grouped together for the analysis since the number of homozygous AA was too low to provide adequate statistical power.

Expression analysis and identification of transcription factor binding sites and conserved regions in LEP and ADIPOQ genes

mRNA levels in SAT and VAT were quantified by quantitative real-time PCR (qRT-PCR). CDNA (cDNA) was generated from total RNA using a random primer hexamer provided with the High Capacity cDNA Archive Kit from Applied Biosystems. Equal amounts of cDNA were run in duplicate and amplified in a 20 µL reaction containing 10 µL of Universal PCR Master Mix (Applied Biosystems). Primers and Taqman probes were obtained from Applied Biosystems (LEP: Hs00174877_m1 and ADIPOQ: Hs00605917_m1). The Glyceraldehyde 3-phosphate dehydrogenase (GAPDH: Hs99999905_m1; Applied Biosystems) housekeeping gene was amplified in parallel. LEP, ADIPOQ, and GAPDH amplifications were performed using the Applied Biosystems 7500 Real Time PCR System, as recommended by the manufacturer (Applied Biosystems). LEP and ADIPOQ mRNA (Ct) levels were quantified relative to change in GAPDH gene expression (Ct). GAPDH/ADIPOQ and GAPDH/LEP Ct ratios (1/x) were used for the analysis.

UCSC genome browser⁴³ and a PubMed literature search were used to identify consensus sequences of TFBS sequence in the LEP gene promoter and ADIPOQ intron 1 DNA sequence. The relationship between LEP and ADIPOQ mRNA regulation and the identified transcription factors was further evaluated with a PubMed literature review.

Statistical analyses

The normal distribution of all variables was assessed using a Kolmogorov–Smirnov test. DNA methylation levels at the ADIPOQ-CpGE1, E2, and E3 loci in blood were not normally distributed. Hence, DNA methylation levels at the ADIPOQ gene locus were compared between blood, SAT, and VAT using the Wilcoxon signed-rank test, whereas paired sample t test was used for LEP gene loci cross-tissue comparisons. In addition, partial Pearson correlation and Spearman correlations were used to determine DNA methylation correlations across the three tissues for the LEP and ADIPOQ gene loci respectively. The associations between adipokines DNA methylation and mRNA levels were also assessed with partial Pearson correlations. Additionally, two-way ANOVA with interaction terms were used to determine the independent variables contributing to LEP mRNA level variance. The Student t test was used to compare DNA methylation and mRNA levels between LEP rs2167270GG genotypes (GG vs GA/AA). Anthropometric characteristics were also compared between men and women using the unpaired Student t test, while categorical variables were compared using the chi-square statistic. Because a large number of tests was performed, Bonferroni multiple testing corrections were applied. Results were therefore considered statistically significant when P values ≤ 4.5 × 10⁻⁴ (P ≤ 0.01) and P values ≤ 2.3 × 10⁻³ (P ≤ 0.05) (two-sided). All statistical analyses were performed with the IBM SPSS Statistics 20 software (release 20.0.0, SPSS).

Abbreviations:
ADIPOQ	=	adiponectin
BMI	=	body mass index
C/EBP	=	CCAAT/enhancer binding protein
HLF	=	hepatic leukemia factor
IGT	=	impaired glucose tolerance
LEP	=	leptin
MIF-1	=	macrophage migration inhibitory factor
RIN	=	RNA integrity number
SAT	=	subcutaneous adipose tissue
TFBS	=	transcription factor binding site
VAT	=	visceral adipose tissue

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors acknowledge the contribution of bariatric surgeons (S. Biron, S. Marceau, O. Lescelleur, L. Biertho) for tissue collection. The authors also express their gratitude to Céline Bélanger, Chicoutimi Hospital, for her thoughtful language revision of the manuscript. A.T. is the director of a Research Chair in Bariatric and Metabolic Surgery. M.C.V. is the recipient of the Canada Research Chair in Genomics Applied to Nutrition and Health. During this research, A.A.H. was a recipient of a FRQS doctoral training award. M.F.H. is supported by a Canadian Diabetes Association clinical scientist award. L.B. and M.F.H. are junior research scholars from the Fonds de recherche du Québec – Santé (FRQS) and members of the FRQS-funded Centre de recherche clinique Étienne-Le Bel (affiliated to Centre Hospitalier de l’Université de Sherbrooke). This project was supported by the Canadian Institutes of Health Research and the FRQS.

10.4161/adip.28308